Paclitaxel for second-line treatment of squamous cell carcinoma of the head and neck: A multicenter retrospective Italian study

Table 6 Palliative chemotherapy data and salvage chemotherapy after immunotherapy

Ref.	n	Baseline characteristics	ChT regimen	Objective response rate	Overall survival	Progression-free survival
Vermorken, 2007	1031	Median age 57 years; male 82; median KPS 80; locoregional only 52	Cetuximab	13	5.9 months	2.3 months
Grau, 2009	60	Median age 59.5 years; male 91.7; KPS 0 1.7; locoregional only 51.7	Paclitaxel	43.3	5.2 months	6.2 months
Tahara, 2011	72	Median age 61 years; male 77.8; KPS 0 66.7; locoregional only n/a	Paclitaxel	33.3	14.3 months	/
Fayette, 2010	66	Median age 60.7 years; male 89; KPS 0 6; locoregional only 58	Paclitaxel, paclitaxel combination	30	7.8 months	3.9 months
Catimel, 1994	40	Median age 55 years; male 32; KPS 0 11; locoregional only 26	Docetaxel	32	/	/
Saleh, 2019	82	Median age 58 years; Male 84; KPS 0 45-55; locoregional only 41	Taxane, taxane cetuximab +/- platinum, taxane platinum, EXTREME, docetaxel-platinum-cetuximab, carboplatin cetuximab, carboplatin paclitaxel	30	7.8 months	3.6 months
Kurosaki, 2021	22	Median age 65 years; male 59.1; KPS 0 22.7; locoregional only 31.8	Cetuximab-paclitaxel, carboplatin fluorouracil cetuximab	40.9	14.5 months	5.2 months
Pestana, 2020	43	Median age n/a; male 90.7; KPS 0; locoregional only 83.7	Cetuximab, single agent ChT, ChT + cetuximab, ChT + other agents	42	8.41 months	4.24 months
Cabezas-Camarero, 2021	23	Median age 65 years; male 73.9; KPS 0 4.3; locoregional only 17.4	ERBITAX, EXTREME, CARBITAX, cisplatin-cetuximab	56.5	12 months	6 months
Harrington, 2023	311	Median age; male; KPS 0; locoregional only	Taxane-based, non-taxane-based (antimetabolite, platinum-based)	N/A	N/A	Pembrolizumab alone; taxane-based: 9.8 months; non-taxane-based: 9.5 months; pembrolizumab-ChT; taxane-based: 12.7 months; non-taxane-based: 12.5 months

¹Intention to treat population only.

ChT: Chemotherapy; KPS: Karnofsky Performance Scale; N/A: Not applicable.